Do GLP-1 Weight Loss Drugs Increase Thyroid Cancer Risk? A Meta-Analysis of 64 Trials

This was a systematic review and meta-analysis of randomized controlled trials comparing any GLP-1 receptor agonist to any comparator. Included trials had to last at least 52 weeks and report adverse event incidence. Researchers collected all thyroid cancer cases across 64 eligible trials and calculated pooled odds ratios using the Mantel-Haenszel method. They also performed subgroup analyses by cancer subtype and trial duration.

With tens of millions of people now taking GLP-1 drugs like Ozempic and Mounjaro, even a small increase in cancer risk has enormous public health implications. Rodent studies had previously shown thyroid tumors with GLP-1 drugs, but human data has been unclear. This is one of the largest meta-analyses to specifically examine thyroid cancer risk with GLP-1 receptor agonists using only randomized trial data — the gold standard for causality assessment.

The GLP-1 drug class has become the fastest-growing pharmaceutical category in history, prescribed for diabetes, obesity, and increasingly being studied for heart disease, kidney disease, and addiction. Regulatory agencies have required thyroid cancer warnings on GLP-1 drug labels based on animal data, but human evidence has been inconsistent. This meta-analysis provides the most rigorous evidence to date of a small but real signal, while also showing the absolute risk is low. The debate now shifts to whether longer-term surveillance will confirm or refute this finding as more patients take these drugs for years or decades.

The fragility index of 1 means the overall finding is statistically fragile — a single event change would make it non-significant. Most trials were designed to study diabetes or weight loss, not cancer, so thyroid cancer detection may have been inconsistent across studies. The longest trials were still relatively short for cancer development, and the subtype-specific analyses (papillary, medullary) were underpowered. The meta-analysis cannot determine whether specific GLP-1 drugs carry more or less risk than others.